iTAF11-4
ICGi025-A
General
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 1-4 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46,XY,r(8)(p23;q24.3)[2]/45,XY,–8[1]. arr[hg19] 8p23.3-p23.1(191530_8079920)×1 dn, 8p11.22-p23.1(12467484_39587538)×3 dn, 9p21.1(28604283_28758185)×1 mat. nuc ish (D8Z2×1)[258/499]
Karyotyping method:
Array CGH
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA7178106 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | No |
| a non-profit company? | No |
| a for-profit corporation? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRM |
| Approval number | 106/2017 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRM |
| Approval number | 106/2017 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell line name | TAF11 |
| Source cell type | |
| Source cell origin |
A human upper limb; especially: the part between the shoulder and the wrist.
|
| Age of donor (at collection) | 1-4 |
| Collected in | 2019 |
| Passage number reprogrammed | 4 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | ||||||||||||||||||
| Feeder cells |
mouse embryonic fibroblast cell Cellfinder Ont Id: EFO:0004040 |
||||||||||||||||||
| Passage method | Mechanically | ||||||||||||||||||
| CO2 Concentration | 5 % | ||||||||||||||||||
| Medium |
Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| TRA 1-60 |
Yes |
|
||||
| NANOG |
Yes |
|||||
| SSEA-4 |
Yes |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| AFP |
Yes |
| HNF1A |
Yes |
| SOX17 |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| MSX1 |
Yes |
| FLK1 |
Yes |
| TBXT |
Yes |
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY,r(8)(p23;q24.3)[88]/45,XY,–8[11]. arr[hg19] 8p23.3-p23.1(191530_8079920)×1 dn, 8p11.22-p23.1(12467484_39587538)×3 dn, 9p21.1(28604283_28758185)×1 mat. nuc ish (D8Z2×1)
Passage number: 4
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.